This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Dermatology

Dermatology; wounds

Hydroxysteroid 11b dehydrogenase 1 (HSD11B1; HSD1)

Studies in mice and in human samples suggest inhibiting HSD11B1 could help prevent age-associated skin defects and improve wound healing. Skin samples from aged individuals showed greater HSD11B1 activity than samples from young individuals. In mice, Hsd11b1 knockout prevented age-associated dermal atrophy compared with no knockout. In injured mice, a topical HSD11B1 inhibitor accelerated wound healing compared with vehicle. Next steps include studies to determine whether preventing age-induced increases in skin HSD11B1 activity or treating skin with HSD11B1 inhibitors can counteract age-induced impairments in skin function.
Eli Lilly and Co.'s LY2523199, an HSD11B1 inhibitor, is in Phase II testing to treat diabetes.
At least four other companies have HSD11B1 inhibitors in Phase I testing or earlier to treat diabetes or glaucoma.

SciBX 6(25); doi:10.1038/scibx.2013.624
Published online June 27, 2013

Patent and licensing status unavailable

Tiganescu, A. et al. J. Clin. Invest.; published online June 3, 2013;
doi:10.1172/JCI64162
Contact: Ana Tiganescu, University of California, San Francisco-NCIRE, San Francisco, Calif.
e-mail:
ana.tiganescu@ncire.org